Leukogene Therapeutics Announces Two Presentations at the AACR Annual Meeting 2026 Highlighting MHC Class II-Engager Immunotherapies CHARLESTON, S.C.–(BUSINESS WIRE)–Leukogene Therapeutics, Inc., an early‑stage oncology company developing MHC class II-engager immunotherapies…

A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia Lena Golick, Reeder M. Robinson, Leticia Reyes, Nadia St. Thomas, Kathleen Klinzing, Erin C. O’Connor, Leonardo…

Leukogene Therapeutics Receives Strategic Funding from South Carolina Research Authority to Accelerate Development of Its Cancer Immunotherapy Pipeline   CHARLESTON, S.C.– (BUSINESS WIRE)– November 12, 2025 –Leukogene Therapeutics Inc., a…

U.S. FDA Grants Orphan Drug Designation to Leukogene Therapeutics’ M2T-CD33 (LTI-214) for the Treatment of Acute Myeloid Leukemia   CHARLESTON, S.C.–(BUSINESS WIRE)– November 5, 2025 –Leukogene Therapeutics Inc. (LTI), a…

Leukogene Therapeutics is the first investment of the 1824 Venture Fund MUSC to launch first venture fund, 1824 Health Ventures Charleston, South Carolina – September 9, 2025 – The Medical…

CHARLESTON, S.C.–(BUSINESS WIRE)–Leukogene Therapeutics Inc., a biotech company with the mission to deliver innovative immunotherapies for hard-to-treat cancers and emphasis on immunologically “cold” tumors, announced today the appointment of Dr.…

SCRA awarded the Medical University of South Carolina $870,000. MUSC has $397,000 in matching funds for a total of over one million dollars to bring three innovations into the marketplace.…